Improved cancer patient care driven by data
We are contributing to this work by:
Developing
innovative molecular tests, for identifying the characteristics of the tumor.
Collecting and storing
knowledge of and information about the patient and their tumor.
Integrating
the information and knowledge with treatment outcome to accelerate scientific research. This enables us to learn from the data of today’s patients and provide better treatment for the patients of tomorrow.
Share your data
Your contribution to improving the treatment of tomorrow’s patients is important. Share your data, too!
Read moreShare your data and share our vision for the future of cancer diagnosis
Read the latest news
Metastatic bladder cancer: new insights into tumour spread and chemotherapy resistance
Hartwig data supports new Nature study on lethal metastatic bladder cancer. Researchers used the Hartwig Medical Database to independently validate …
Why genomes need clinical data: new Nature study uses Hartwig real world data to test a prostate cancer biomarker
Understanding prostate cancer’s clinical heterogeneity A new study in Nature investigates the mutational processes behind prostate cancer’s clinical heterogeneity and …
Hartwig advances precision oncology worldwide with oncoanalyser
Nicole Schonrock on scaling precision care for patients with cancer in Australia Hartwig Medical Foundation has developed powerful software for …
Oncoanalyser 3.0 for cancer genomics is out, now also supporting Ultima Genomics & Roche platforms
Extensive work on the underlying WiGiTS tools now enable users to analyze sequencing data from three sequencing platforms (Illumina, Ultima …
New study using Hartwig Medical Foundation data maps how breast cancer’s genetic makeup shifts when it spreads
Analysis of nearly 1,300 tumor genomes across ten genomic subtypes points to candidate drug targets and biomarkers for metastatic breast …
Hartwig receives CE certification for OncoAct, the first complete IVDR-certified whole-genome cancer diagnostics solution
We are proud to announce that Hartwig Medical Foundation has received CE certification under the European In Vitro Diagnostic Regulation …
Read the latest blogs
Expansion of the Hartwig Client Portal: registration becomes easier, safer, and smarter
The expansion of the Hartwig Client Portal marks another important step in further digitizing the collaboration between Hartwig Medical Foundation …
Read more
DataNexus connects clinical and genomic data
DataNexus is a project initiated by the Netherlands Cancer Institute–Antoni van Leeuwenhoek (NKIAvL) to improve data availability by integrating clinical …
Read more
How do you analyze 8,000 Tumor/Normal genomes in under two months?
It has been a long time coming: Hartwig Medical Foundation has transitioned to the GRCh38 (hg38) reference genome! For years, …
Read more
More and more cancer drugs are only suitable for a small group of patients. However, we are often not capable to find these patients. That is why every patient with metastatic cancer should be genetically screened before starting treatment.